Jeffrey Meyehardt, MD of Harvard Medical School discusses the use of vemurafenib in BRAF+ mutated metastatic colorectal cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
Have you adopted vemurafenib in BRAF+ mutated metastatic CRC?
Jeffrey Meyehardt, MD of Harvard Medical School discusses the use of vemurafenib in BRAF+ mutated metastatic colorectal cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.